Response.

Response.

Reader Response: Pediatric and Adult Brain Death/Death by Neurologic Criteria Consensus Guideline: Report of the AAN Guidelines Subcommittee, AAP, CNS, and SCCM.

A Biophilosophical Approach to the Determination of Brain Death.

Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature Review.

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.

Monkeypox-Associated Central Nervous System Disease: A Case Series and Review.

Identification of cognitive impairment, depression, and fatigue among multiple sclerosis patients in a large comprehensive care center: A mixed-methods, qualitative study.

Two Cases of Monkeypox-Associated Encephalomyelitis - Colorado and the District of Columbia, July-August 2022.

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide.

From publications to every day clinical practice: tocilizumab in patients with severe COVID-19.

Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.

Recurrent Thymoma-Associated Paraneoplastic Encephalitis Resulting From Multiple Antibodies: A Case Report.

Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations.

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.